Identifying an Early Improvement Cutoff in Psoriasis Area and Severity Index for Outcome Prediction Across Systemic Treatments
Open Access
- 1 January 2026
- journal article
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Abstract
Background: Early identification of treatment response is clinically important in psoriasis management, as it may facilitate timely treatment modification and reduce exposure to ineffective therapies. Although early improvement in the Psoriasis Area and Severity Index (PASI) has been associated with long‐term outcomes for individual therapies, a broadly applicable early PASI threshold across different treatment modalities in real‐world practice remains unclear. Objectives: To evaluate the predictive value of early PASI improvement for subsequent PASI90 achievement across multiple psoriasis treatment modalities and to identify a clinically meaningful early PASI response threshold. Methods: This prospective, multicenter real‐world cohort study (approval no. 2020‐36) included adult patients with moderate‐to‐severe plaque psoriasis receiving methotrexate, phototherapy, interleukin (IL)‐17 inhibitors, or IL‐23 inhibitors. Receiver operating characteristic (ROC) curve analyses were used to evaluate the predictive performance of week‐4 PASI improvement for achieving PASI90 at 3 and 6 months. The optimal early response threshold was identified using the Youden Index. Multivariable logistic regression analyses were conducted to assess the independent association between early PASI response and subsequent PASI90 achievement. Results: A total of 2023 patients were included in the analysis. The optimal week‐4 PASI improvement threshold for predicting PASI90 at 3 months was 62% for IL‐17 inhibitors, 62% for IL‐23 inhibitors, 59% for methotrexate, and 61% for phototherapy. Multivariable logistic regression analyses further demonstrated that a PASI improvement of approximately 60% at Week 4 was independently associated with a higher likelihood of achieving PASI90 at 3 months. Conclusions: Achieving PASI60 at Week 4 serves as a consistent early indicator of subsequent PASI90 response across multiple psoriasis treatment modalities. These findings suggest that PASI60 may represent a potentially generalizable early‐response threshold; however, external validation in independent populations is required before its incorporation into routine clinical decision‐making. Trial Registration: Chinese Clinical Trial Registry: ChiCTR2000036186Keywords
Funding Information
- National Natural Science Foundation of China (81872522)
- National Natural Science Foundation of China (82073429)
- National Natural Science Foundation of China (82203913)
- Shanghai Municipal Education Commission (2019-01-07-00-07-E00046)
- Shanghai Shen Kang Hospital Development Center (SHDC2020CR1014B)
- Program of Shanghai Academic Research Leader (20XD1403300)
- Fundamental Research Funds for the Central Universities (22120220602)
This publication has 23 references indexed in Scilit:
- Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-AnalysisDermatology and Therapy, 2025
- Early response is a strong predictor of the long-term response in psoriasis patients receiving risankizumab or guselkumab in the real-world: a retrospective analysisExpert Review of Clinical Pharmacology, 2025
- Signaling pathways and targeted therapies for psoriasisSignal Transduction and Targeted Therapy, 2023
- PsoriasisThe Lancet, 2021
- Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasisJournal of Dermatological Treatment, 2021
- A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trialBritish Journal of Dermatology, 2019
- Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapyJournal of the American Academy of Dermatology, 2019
- Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trialsJournal of the American Academy of Dermatology, 2017
- Biologic therapy for psoriasis: early response implies future successBritish Journal of Dermatology, 2013
- Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasisBritish Journal of Dermatology, 2013